| Purpose | Board Meetings Date | Announcement Date |
|---|---|---|
| Board Meeting | 28 Jan 2025 | 17 Jan 2025 |
| Jubilant Ingrevia Ltdhas informed BSE that the meeting of the Board of Directors of the Company is scheduled on 28/01/2025 ,inter alia, to consider and approve Unaudited Financial results for quarter ended 31st December, 2024 and proposal for interim dividend. Board declares interim dividend (As Per BSE Announcement Dated on 28.01.2025) | ||
| Board Meeting | 22 Oct 2024 | 11 Oct 2024 |
| Jubilant Ingrevia Ltdhas informed BSE that the meeting of the Board of Directors of the Company is scheduled on 22/10/2024 inter alia to consider and approve Unaudited Standalone and Consolidated Financial Results Outcome of Board Meeting Unaudited financial results for quarter ending 30 September 2024 (As Per BSE Announcement Dated on 22.10.2024) | ||
| Board Meeting | 16 Jul 2024 | 9 Jul 2024 |
| Jubilant Ingrevia Ltdhas informed BSE that the meeting of the Board of Directors of the Company is scheduled on 16/07/2024 inter alia to consider and approve unaudited Financial Results for the quarter ended 30 June 2024 Approval of unaudited Standalone and Consolidated Financial Results (As Per BSE Announcement dated on 16.07.2024) | ||
| Board Meeting | 26 Jun 2024 | 26 Jun 2024 |
| Appointment of Chief Financial Officer | ||
| Board Meeting | 14 May 2024 | 3 May 2024 |
| Jubilant Ingrevia Ltdhas informed BSE that the meeting of the Board of Directors of the Company is scheduled on 14/05/2024 inter alia to consider and approve Intimation for Board Meeting and Final Dividend The Board at its meeting held on May 14, 2024 has recommended the final dividend. Re-appointment of Cost Auditors for FY 2024-25 Record Date is fixed as August 2, 2024 Audited Standalone and Consolidated financial results for the quarter and year ended March 31, 2024 along with Auditors Report (As Per BSE Announcement dated on 14.05.2024) | ||
The board approved this acquisition on December 30, 2024. The equity bought of 6.67% was from Hero Fincorp Ltd and Sunil Kant Munjal.
In Q2 FY25, the company's total EBITDA increased by 7% year on year to ₹135 Crore, up from ₹126 Crore the previous year.
The company stated that its production facility in Bharuch successfully completed its USFDA inspection with zero 483 findings.
Invest wise with Expert advice
IIFL Customer Care Number
(Gold/NCD/NBFC/Insurance/NPS)
1860-267-3000 / 7039-050-000
IIFL Capital Services Support WhatsApp Number
+91 9892691696
Download The App Now
Follow us on
2025, IIFL Capital Services Ltd. All Rights Reserved
IIFL Securities Limited - Stock Broker SEBI Regn. No: INZ000164132, PMS SEBI Regn. No: INP000002213,IA SEBI Regn. No: INA000000623, SEBI RA Regn. No: INH000000248
This Certificate Demonstrates That IIFL As An Organization Has Defined And Put In Place Best-Practice Information Security Processes.
